Press Releases

Date Title and Summary
Toggle Summary Accuray to Participate in the B. Riley Securities' 3rd Annual Oncology Conference
Company to Take Part in Fireside Chat Wednesday, January 18, 2023 at 7:00am PST / 10:00am EST SUNNYVALE, Calif. , Jan. 10, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the B. Riley Securities' 3rd Annual Oncology Conference taking place January
Toggle Summary Accuray Receives IMV Award for Best In Service in Radiation Oncology for 2022
SUNNYVALE, Calif. , Nov. 28, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its commitment to delivering better, faster cancer treatment technology and superior service is resulting in highly satisfied customers. According to the IMV ServiceTrak™ Radiation Oncology
Toggle Summary Oscar Lambret Center in France Installs Second Accuray Radixact® System, the Hospital's Fifth Accuray Radiation Therapy Delivery System
Hospital Adds Accuray ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony ® Technologies to Both Radixact Systems, Creating the Ultimate System for Personalized Cancer Care SUNNYVALE, Calif. , Nov. 16, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Oscar Lambret
Toggle Summary Accuray Reports Fiscal 2023 First Quarter Financial Results
Strong customer demand. Navigating FX and Supply Chain Challenges. Company reiterates full year guidance.  SUNNYVALE, Calif. , Nov. 2, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2023 ended September 30, 2022 .
Toggle Summary Accuray Announces Tomo® C Registration Submission to China's National Medical Products Administration
SUNNYVALE, Calif. , Nov. 1, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo ® C radiation therapy system for the Type B market has been submitted to the Chinese National Medical Products Administration
Toggle Summary New Reimbursement Approved by the Japanese Ministry of Health, Labor and Welfare for the Accuray CyberKnife® System to Treat Trigeminal Neuralgia, a Condition Often Causing Severe Facial Pain
SUNNYVALE, Calif. , Oct. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved reimbursement for the CyberKnife ® System for the treatment of trigeminal neuralgia (TN).
Toggle Summary GE Healthcare and Accuray Collaborate to Expand Access, Advance the Practice of Precision Radiation Therapy
Collaboration places emphasis on personalized medicine; brings together key precision diagnostic and treatment delivery tools aimed at creating shorter, more comfortable and more effective treatments for patients CHICAGO and SUNNYVALE, Calif. , Oct. 21, 2022 /PRNewswire/ -- GE Healthcare and
Toggle Summary Accuray to Report First Quarter Fiscal 2023 Financial Results on November 2, 2022
SUNNYVALE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2023, ended September 30, 2022, after the market close on November 2, 2022. Management will host a conference call to review the results at 1:30
Toggle Summary Accuray and C-RAD Unveil Automated Breast Cancer Treatment Package for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
SUNNYVALE, Calif. , Oct. 13, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company, in partnership with C-RAD AB (NASDAQ Stockholm: CRAD B), will showcase an important new option for improving the care of people diagnosed with breast cancer during the 2022 ASTRO (
Toggle Summary Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators
Latest research published in The Lancet Oncology : suggests bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment Almost 20 years of global clinical data: shows the non-surgical CyberKnife platform

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at and on the SEC's website at